Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer.
anti-cancer effects
green tea
molecular mechanism
prostate cancer
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
07 Jan 2019
07 Jan 2019
Historique:
received:
22
10
2018
revised:
03
01
2019
accepted:
03
01
2019
entrez:
10
1
2019
pubmed:
10
1
2019
medline:
16
3
2019
Statut:
epublish
Résumé
Prostate cancer is the most common cancer among men. Green tea consumption is reported to play an important role in the prevention of carcinogenesis in many types of malignancies, including prostate cancer; however, epidemiological studies show conflicting results regarding these anti-cancer effects. In recent years, in addition to prevention, many investigators have shown the efficacy and safety of green tea polyphenols and combination therapies with green tea extracts and anti-cancer agents in in vivo and in vitro studies. Furthermore, numerous studies have revealed the molecular mechanisms of the anti-cancer effects of green tea extracts. We believe that improved understanding of the detailed pathological roles at the molecular level is important to evaluate the prevention and treatment of prostate cancer. Therefore, in this review, we present current knowledge regarding the anti-cancer effects of green tea extracts in the prevention and treatment of prostate cancer, with a particular focus on the molecular mechanisms of action, such as influencing tumor growth, apoptosis, androgen receptor signaling, cell cycle, and various malignant behaviors. Finally, the future direction for the use of green tea extracts as treatment strategies in patients with prostate cancer is introduced.
Identifiants
pubmed: 30621039
pii: molecules24010193
doi: 10.3390/molecules24010193
pmc: PMC6337309
pii:
doi:
Substances chimiques
Anticarcinogenic Agents
0
Antioxidants
0
Polyphenols
0
Tea
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51
pubmed: 10357558
Ann N Y Acad Sci. 1999 Jun 30;878:271-89
pubmed: 10415736
Oncogene. 1999 Jul 29;18(30):4301-12
pubmed: 10439038
Am J Pathol. 1999 Dec;155(6):1985-92
pubmed: 10595928
Toxicol Appl Pharmacol. 2000 Apr 1;164(1):82-90
pubmed: 10739747
Oncogene. 2000 Apr 6;19(15):1924-32
pubmed: 10773882
J Urol. 2000 Sep;164(3 Pt 1):722-5
pubmed: 10953133
Biochem Pharmacol. 2000 Oct 15;60(8):1051-9
pubmed: 11007941
Urology. 2000 Nov 1;56(5):828-32
pubmed: 11068311
Clin Cancer Res. 2000 Nov;6(11):4234-42
pubmed: 11106237
Prostate. 2001 Feb 1;46(2):98-107
pubmed: 11170137
Life Sci. 2001 Jan 26;68(10):1207-14
pubmed: 11228105
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10350-5
pubmed: 11504910
Methods Mol Biol. 2002;172:69-80
pubmed: 11833360
Prostate. 2003 Feb 1;54(2):125-32
pubmed: 12497585
Arch Biochem Biophys. 2003 Feb 1;410(1):177-85
pubmed: 12559991
Prostate. 2003 May 15;55(3):219-37
pubmed: 12692788
Oncogene. 2003 Jul 31;22(31):4851-9
pubmed: 12894226
Biochem Pharmacol. 2003 Sep 15;66(6):965-76
pubmed: 12963483
Br J Cancer. 2003 Nov 17;89(10):1817-21
pubmed: 14612884
Int J Cancer. 2004 Jan 1;108(1):130-5
pubmed: 14618627
J Cell Biochem. 2004 Feb 1;91(2):232-42
pubmed: 14743383
Nutr Cancer. 2003;47(1):13-23
pubmed: 14769533
Prostate. 2004 Apr 1;59(1):33-42
pubmed: 14991864
Cancer Sci. 2004 Mar;95(3):238-42
pubmed: 15016323
Nat Struct Mol Biol. 2004 Apr;11(4):380-1
pubmed: 15024383
Urology. 2004 Mar;63(3):602-8
pubmed: 15028476
Urol Clin North Am. 2004 May;31(2):301-11
pubmed: 15123409
Anticancer Res. 2004 May-Jun;24(3a):1797-804
pubmed: 15274358
Carcinogenesis. 2004 Nov;25(11):2217-24
pubmed: 15358631
Int J Cancer. 2005 Feb 10;113(4):660-9
pubmed: 15455372
Cancer Res. 2004 Dec 1;64(23):8715-22
pubmed: 15574782
Cancer Causes Control. 2004 Nov;15(9):911-20
pubmed: 15577293
J Urol. 2005 Jan;173(1):56-60
pubmed: 15592025
Clin Cancer Res. 2005 Jan 1;11(1):147-53
pubmed: 15671539
J Urol. 2005 Aug;174(2):461-5
pubmed: 16006865
Carcinogenesis. 2006 Apr;27(4):833-9
pubmed: 16387739
Cancer Res. 2006 Jan 15;66(2):1234-40
pubmed: 16424063
J Androl. 2006 Nov-Dec;27(6):725-8
pubmed: 16775253
Br J Cancer. 2006 Aug 7;95(3):371-3
pubmed: 16804523
Life Sci. 2006 Nov 17;79(25):2329-36
pubmed: 16945390
Cancer Control. 2007 Jan;14(1):78-85
pubmed: 17242674
Clin Cancer Res. 2007 Mar 1;13(5):1611-9
pubmed: 17332308
Prostate. 2007 Oct 1;67(14):1576-89
pubmed: 17705241
Oncogene. 2008 Mar 13;27(12):1788-93
pubmed: 17891175
Am J Epidemiol. 2008 Jan 1;167(1):71-7
pubmed: 17906295
Prostate Cancer Prostatic Dis. 2008;11(2):112-20
pubmed: 17998918
Pharm Res. 2008 Sep;25(9):2135-42
pubmed: 18317887
Eur Urol. 2008 Aug;54(2):472-3
pubmed: 18406041
Mol Oncol. 2007 Sep;1(2):196-204
pubmed: 18521193
Prostate. 2009 Feb 1;69(2):219-24
pubmed: 18942120
Cancer Lett. 2009 Mar 8;275(1):86-92
pubmed: 18977589
J Nutr. 2009 Jan;139(1):58-62
pubmed: 19056646
Hum Pathol. 2009 Apr;40(4):496-504
pubmed: 19121849
Int J Cancer. 2009 May 15;124(10):2416-29
pubmed: 19142965
Clin Cancer Res. 2009 Mar 15;15(6):1947-53
pubmed: 19276266
Asian J Androl. 2009 May;11(3):362-70
pubmed: 19330017
Cancer Prev Res (Phila). 2009 Jul;2(7):673-82
pubmed: 19542190
Oncogene. 2009 Sep 24;28(38):3360-70
pubmed: 19597470
Cancer Res. 2009 Sep 15;69(18):7165-9
pubmed: 19738047
Oncogene. 2009 Dec 10;28(49):4344-52
pubmed: 19784068
Adv Cancer Res. 2009;105:115-32
pubmed: 19879426
Phytomedicine. 2010 Jan;17(1):3-13
pubmed: 19959000
FASEB J. 2011 Apr;25(4):1198-207
pubmed: 21177307
Cancer Lett. 2011 Aug 28;307(2):200-10
pubmed: 21536375
Cancer Manag Res. 2011;3:91-100
pubmed: 21629831
Nutr Cancer. 2011;63(5):663-72
pubmed: 21667398
Ann N Y Acad Sci. 2011 Jul;1229:124-32
pubmed: 21793847
Oncol Rep. 2011 Dec;26(6):1407-13
pubmed: 21874261
Cancer Prev Res (Phila). 2012 Feb;5(2):290-8
pubmed: 22044694
Nutr Cancer. 2012;64(1):4-22
pubmed: 22098273
Int J Mol Med. 2012 Jul;30(1):69-74
pubmed: 22505206
Oxid Med Cell Longev. 2012;2012:984219
pubmed: 22666523
Cancer Causes Control. 2012 Oct;23(10):1635-41
pubmed: 22864870
Oncol Lett. 2010 May;1(3):417-421
pubmed: 22966318
Exp Ther Med. 2010 Jan;1(1):27-31
pubmed: 23136588
Cancer Treat Rev. 2014 Feb;40(1):31-40
pubmed: 23993415
Am J Clin Nutr. 2013 Dec;98(6 Suppl):1676S-1681S
pubmed: 24172305
J Nutr Biochem. 2014 Jan;25(1):73-80
pubmed: 24314868
Carcinogenesis. 2014 Apr;35(4):828-39
pubmed: 24343359
Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27
pubmed: 24384911
World J Surg Oncol. 2014 Feb 14;12:38
pubmed: 24528523
Nat Rev Urol. 2014 Apr;11(4):197-212
pubmed: 24595118
BMC Cancer. 2014 May 30;14:387
pubmed: 24885350
J Inflamm Res. 2014 Jun 17;7:89-101
pubmed: 24971028
Biomed Environ Sci. 2014 Sep;27(9):707-17
pubmed: 25256860
Prostate. 2015 Jan;75(1):84-91
pubmed: 25307287
J Cancer Res Clin Oncol. 2015 Apr;141(4):627-31
pubmed: 25323935
Cancer Prev Res (Phila). 2015 Mar;8(3):249-57
pubmed: 25604133
Front Endocrinol (Lausanne). 2015 Jan 19;5:225
pubmed: 25646090
Biomed Res Int. 2015;2015:121826
pubmed: 25821782
Cancer Prev Res (Phila). 2015 Oct;8(10):879-87
pubmed: 25873370
Int J Clin Exp Med. 2015 Feb 15;8(2):2289-98
pubmed: 25932165
Prostate. 2015 Nov;75(15):1726-36
pubmed: 26202060
Sci Rep. 2015 Oct 16;5:15270
pubmed: 26471237
Adv Biol Regul. 2016 Jan;60:64-87
pubmed: 26525204
Int J Biochem Cell Biol. 2016 Aug;77(Pt A):91-101
pubmed: 27267661
Medicine (Baltimore). 2016 Jun;95(24):e3904
pubmed: 27310993
Minerva Urol Nefrol. 2017 Aug;69(4):324-329
pubmed: 27355218
PLoS One. 2017 Mar 16;12(3):e0173641
pubmed: 28301518
Medicine (Baltimore). 2017 Mar;96(13):e6426
pubmed: 28353571
Antioxidants (Basel). 2017 Apr 05;6(2):
pubmed: 28379200
Cancers (Basel). 2017 Apr 10;9(4):null
pubmed: 28394264
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):318-322
pubmed: 28417981
Oncol Lett. 2017 Jun;13(6):4571-4576
pubmed: 28588719
Oncol Lett. 2017 Jun;13(6):4995-5001
pubmed: 28588738
Biochem Biophys Res Commun. 2018 May 27;500(1):26-34
pubmed: 28676391
Anat Rec (Hoboken). 2017 Dec;300(12):2184-2191
pubmed: 28921916
Oncotarget. 2017 Jul 26;8(46):80568-80588
pubmed: 29113326
Cancer Res. 1989 Apr 1;49(7):1857-60
pubmed: 2924323
Cancers (Basel). 2017 Dec 16;9(12):null
pubmed: 29258163
Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):null
pubmed: 29311128
Mol Clin Oncol. 2018 Jan;8(1):127-132
pubmed: 29387404
Int J Mol Sci. 2018 Mar 23;19(4):null
pubmed: 29570632
Phytother Res. 2018 Jul;32(7):1163-1180
pubmed: 29575316
Molecules. 2018 Mar 29;23(4):null
pubmed: 29596305
Evid Based Complement Alternat Med. 2018 Feb 28;2018:6328970
pubmed: 29681978
Cancer Epidemiol. 2018 Aug;55:117-122
pubmed: 29936140
Curr Stem Cell Res Ther. 2018 Jul 22;:null
pubmed: 30033874
Mol Med. 2018 Jun 27;24(1):34
pubmed: 30134822
Cells. 2018 Aug 29;7(9):null
pubmed: 30158439
Life Sci. 2018 Nov 15;213:94-101
pubmed: 30179629
Int Immunopharmacol. 2018 Nov;64:162-169
pubmed: 30179845
Genes Dev. 2018 Sep 1;32(17-18):1105-1140
pubmed: 30181359
Dis Markers. 2018 Aug 16;2018:3852401
pubmed: 30186533
Molecules. 2018 Sep 07;23(9):null
pubmed: 30205425
Breast Cancer. 2018 Sep 25;:
pubmed: 30255294
Cancers (Basel). 2018 Sep 25;10(10):null
pubmed: 30257470
Biochem Biophys Res Commun. 1995 Sep 25;214(3):833-8
pubmed: 7575552
Cancer Lett. 1995 Sep 25;96(2):239-43
pubmed: 7585463
Prostate Suppl. 1996;6:79-81
pubmed: 8630235
J Cell Biochem Suppl. 1996;26:1-28
pubmed: 9154166
J Natl Cancer Inst. 1997 Dec 17;89(24):1881-6
pubmed: 9414176
Cancer Lett. 1998 Aug 14;130(1-2):1-7
pubmed: 9751250